Pharmaceutical manufacturers adopting decentralized trial methodologies are recording measurable reductions in Phase I and Phase II clinical timelines. The shift relies heavily on continuous remote patient monitoring and real-world data integration.
Data Processing Efficiency Gains
Automated data collection protocols have lowered trial participant drop-out rates while improving compliance monitoring. Regulatory agencies are increasingly accepting synthesized control arms, further streamlining approval pathways for targeted therapies.